| Phenotype | Cases = number of cardiovascular deathsHFPGR: Patients with left ventricular ejection fraction (LVEF) <50% were included. Beta-blocker (BB) exposure was calculated from pharmacy claims (ie, drug actually dispensed to patient) and was updated over time. Beta-blocker (BB) exposure was calculated from pharmacy claims (ie, drug actually dispensed to patient) and was updated over time. TIME-CHF: Patients with analysable data and a baseline LVEF <50% were included. BB exposure was calculated from the specific drug and dose at baseline, using the same dose-equivalence scheme as HFPGR but implemented without any updates over time and without information on medication dispensing (ie, assumes patients were receiving the dose prescribed). HF-ACTION: BB exposure was calculated from the specific drug and dose at baseline, using the same dose-equivalence scheme as HFPGR but implemented without any updates over time and without information on medication dispensing (ie, assumes patients were receiving the dose prescribed). |
| Sample Ancestry | European |
| Total number | 1,188 individuals |
| Detailed numbers |
200 cases (16.84%)
988 controls
|
| Number of Cohort(s) | 3 |
| Cohort Short Name | Cohort Full Name | Previous/other/additional names (e.g. sub-cohorts) |
|---|---|---|
| HF-ACTION | Heart Failure: a Controlled Trial Investigating Outcomes of Exercise Training | — |
| HFPGR | Henry Ford Heart Failure Pharmacogenomic Registry | — |
| TIME-CHF | Trial of Intensified Versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure | — |